This segment focuses on the research, development, and clinical trials of the Cellspan Esophageal Implant. The core technology involves a biocompatible scaffold seeded with the patient's own stem cells to regenerate the esophagus. Research and development activities include preclinical studies in animal models and clinical trials in human patients with severe esophageal diseases, including cancer. The goal is to improve patient outcomes by providing a functional and durable replacement for damaged esophageal tissue, addressing the significant unmet medical need in this area. The company is actively working on securing FDA approval and expanding clinical trial sites. Partnerships and collaborations are crucial for clinical trial management and manufacturing. The market positioning is focused on providing a novel solution for esophageal reconstruction, offering a potential advantage over existing treatments.

This segment focuses on extending the Cellframe technology to treat conditions affecting the bronchus and trachea. Research and development efforts are directed towards adapting the Cellframe scaffold and cell-seeding techniques for these specific anatomical locations. The company is working on securing patents for treatments of lung cancer and other respiratory diseases. The therapeutic areas include the treatment of lung cancer and other respiratory diseases. The patient impact will be significant, offering potential solutions for patients with severe airway damage. The market positioning is to provide innovative solutions for airway reconstruction. Future opportunities include expanding the application of the technology to other areas of regenerative medicine. Regulatory and clinical aspects involve securing FDA approval for clinical trials and commercialization. Partnerships and collaborations are essential for clinical trial management and manufacturing.